Zacks Research upgraded shares of Nexalin Technology (NASDAQ:NXL – Free Report) to a hold rating in a report published on Thursday,Zacks reports.
Separately, Weiss Ratings downgraded Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 25th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Nexalin Technology currently has a consensus rating of “Reduce”.
Get Our Latest Stock Analysis on NXL
Nexalin Technology Price Performance
Nexalin Technology (NASDAQ:NXL – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.00) by $2.89. Nexalin Technology had a negative net margin of 4,141.94% and a negative return on equity of 278.24%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.09 million. Research analysts anticipate that Nexalin Technology will post -11.4 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Nexalin Technology
A hedge fund recently bought a new stake in Nexalin Technology stock. PEAK6 LLC bought a new position in Nexalin Technology, Inc. (NASDAQ:NXL – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 240,210 shares of the company’s stock, valued at approximately $79,000. PEAK6 LLC owned approximately 1.09% of Nexalin Technology at the end of the most recent reporting period. 0.65% of the stock is owned by institutional investors and hedge funds.
Nexalin Technology News Summary
Here are the key news stories impacting Nexalin Technology this week:
- Positive Sentiment: Nexalin signed an exclusive distribution and local manufacturing agreement for its ANVISA-approved Nexalin Sync™ neurostimulation device in Brazil and six other South American countries. The initial commercialization program covers 100 devices and a potential market of more than 300 million people, offering a possible path toward commercial revenue and larger government or private-sector contracts. Nexalin South America distribution and manufacturing agreement
- Positive Sentiment: Nexalin said it regained compliance with Nasdaq requirements on September 30. This removes an immediate listing threat, although the company remains exposed to further compliance and trading risks. Nexalin regains Nasdaq compliance
- Neutral Sentiment: Trading in NXL was repeatedly paused under Nasdaq’s Limit Up-Limit Down mechanism on October 1, indicating unusually sharp price movements and heightened speculative activity. The halts do not represent a change in the company’s fundamentals.
- Negative Sentiment: Maxim Group expects Nexalin to report a loss of $2.70 per share in both the third and fourth quarters of 2026, a full-year loss of $11.40 per share, and a $9.30 per-share loss in 2027. These forecasts reinforce concerns about near-term profitability, particularly given the company’s very small revenue base and historically negative margins. Maxim Group NXL earnings forecast
Nexalin Technology Company Profile
Nexalin Technology, Inc is a medical technology company focused on developing noninvasive neurostimulation devices designed to support brain health. Its technology uses cranial electrotherapy stimulation to deliver low-level electrical signals through electrodes placed on the head, with the aim of influencing brain activity without surgery or implanted hardware.
The company’s product portfolio includes the Nexalin Gen-2 and Gen-3 devices, which are designed for use in clinical and other supervised settings.
Further Reading
- Five stocks we like better than Nexalin Technology
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
